Dianeal PD-1 with 1.5% Dextrose (lvp solution) Disease Interactions
There are 2 disease interactions with Dianeal PD-1 with 1.5% Dextrose (lvp solution):
Sodium salts (applies to Dianeal PD-1 with 1.5% Dextrose) sodium/water imbalance
Major Potential Hazard, Moderate plausibility. Applicable conditions: Congestive Heart Failure, Fluid Retention, Hypernatremia, Hypokalemia
Sodium chloride can induce sodium and water retention and result in hypernatremia, hypokalemia, edema and aggravation of congestive heart failure. Therapy with sodium- containing agents should be administered with extreme caution, if at all, in patients with congestive heart failure, severe renal insufficiency, and in clinical states where there is edema with sodium retention. Clinical monitoring of acid/base balance and electrolytes prior to, during, a following completion of therapy with sodium- containing agents is recommended.
- "Product Information. Megace (megestrol)." Bristol-Myers Squibb, Princeton, NJ.
- "Product Information. Calcibind (cellulose sodium phosphate)." Mission Pharmaceutical Company, San Antonio, TX.
- "Product Information. Sodium Benzoate (sodium benzoate)." Taylor Pharmaceuticals, San Clemente, CA.
LVP solution (applies to Dianeal PD-1 with 1.5% Dextrose) hyperglycemia
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus
LVP solution for peritoneal dialysis contains dextrose and may increase the risk for hyperglycemia in patients with impaired glucose tolerance. Patients may require initiation or modification of antidiabetic therapy during treatment with these solutions. Blood glucose should me monitored.
More about Dianeal PD-1 with 1.5% Dextrose (lvp solution)
Related treatment guides
Drug Interaction Classification
|No interaction information available.|